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Abstract
Background: The pathogenesis of contact dermatitis, a common inflammatory skin
disease with limited treatment options, is held to be driven by inflammasome acti-
vation induced by allergens and irritants. We here aim to identify inflammasome‐
targeting treatment strategies for irritant contact dermatitis.
Methods: A high content screen with 41,184 small molecules was performed using
fluorescent Apoptosis associated speck‐like protein containing a CARD (ASC) speck
formation as a readout for inflammasome activation. Hit compounds were validated
for inhibition of interleukin (IL)‐1β secretion. Of these, the approved thiur-
amdisulfide derivative disulfiram was selected and tested in a patch test model of
irritant contact dermatitis in 25 healthy volunteers. Topical application of disulfiram,
mometasone or vehicle was followed by application of sodiumdodecylsulfate (SDS)
for 24 h each. Eczema induction was quantified by mexameter and laser speckle
imaging. Corneocyte sampling of lesional skin was performed to assess
inflammasome‐mediated cytokines IL‐1β and IL‐18.
Results: Disulfiram induced a dose‐dependent inhibition of ASC speck formation
and IL‐1β release in cellular assays in vitro. In vivo, treatment with disulfiram, but
not with vehicle and less mometasone, inhibited SDS‐induced eczema. This was
demonstrated by significantly lower erythema and total perfusion values assessed
by mexameter and laser speckle imaging for disulfiram compared to vehicle
(p < 0.001) and/or mometasone (p < 0.001). Also, corneocyte IL‐18 levels were
significantly reduced after application of disulfiram compared to vehicle (p < 0.001).
Conclusion: We show that disulfiram is a dose‐dependent inhibitor of inflamma-
some pathway activation in vitro and inhibitor of SDS‐induced eczema in vivo.
Topical application of disulfiram represents a potential treatment option for irritant
contact dermatitis.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
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1 | INTRODUCTION
Contact dermatitis is a common chronic inflammatory skin disease
presenting with erythema, papules, vesicles and scaling at the site of
skin contact with irritants or allergens. Its prevalence has markedly
increased, causing high annual societal costs and considerable quality
of life impairment.1 In Europe, about 15% of the general population
suffers from contact dermatitis.2
Current therapeutic strategies in contact dermatitis include the
avoidance of relevant irritants and allergens, the use of emollients,
and treatment with topical glucocorticosteroids, UV‐light, or sys-
temic retinoid treatment in severe disease.3 In many patients, these
treatments are not satisfactory and often come with side effects.
Topical glucocorticosteroids as the standard treatment are often
associated with skin atrophy and immunosuppression, loss of efficacy
over time and insufficient response. Novel and better treatment
options for patients with contact dermatitis are needed.
Chronic hand eczema is the main clinical phenotype of both
irritant and allergic contact dermatitis. It represents the most
frequent occupational disease in Western countries and negatively
affects patients’ ability to work, career development and social sta-
tus. Chronic hand eczema causes significant individual and economic
burden. This includes high rates of depression, anxiety and suicidal
ideation compared to the general population.4 The economic burden
originates from sick leave because of the condition, the need to
change the workplace or profession and unemployment.5 Of note, the
intensive hand hygiene during the COVID‐19 pandemic has already
increased the incidence of chronic hand eczema.6
Allergic contact dermatitis is a T cell‐driven, delayed‐type IV
hypersensitivity reaction to allergens that requires prior sensitization
of a susceptible individual to the respective allergen. Most exogenous
substances such as chemicals or metals function as haptens that may
become full allergens only by binding to protein carriers in the skin.
Innate immune sensing followed by an inflammatory milieu induces
the migration of dendritic cells to lymphoid organs and presentation
of hapten‐protein complexes to naïve T cells. Following sensitization,
subsequent re‐exposure to the hapten leads to activation and influx
of inflammatory cells such as hapten‐specific effector and memory T
cells as well as neutrophils promoting the activation of skin mast cells.
Cytotoxic CD8+ T cells kill haptenized keratinocytes and induce via
mobilization of further inflammatory cells the formation of eczema-
tous skin lesions.7 In contrast, irritant contact dermatitis occurs via a
direct toxic effect on epidermal corneocytes and keratinocytes by an
irritant (e.g., chemical) with subsequent barrier disruption and
inflammation without involvement of adaptive immune mechanisms.
Irritants may trigger cell necrosis and the release of stress signals (e.
g., reactive oxygen species, ATP) and damage‐associated molecular
patterns (e.g., heat‐shock proteins) which are sensed by receptors of
innate immune cells.7 The pathogenesis of both, allergic and irritant
contact dermatitis is held to be driven, at least in part, by the acti-
vation of the NLR family pyrin domain containing 3 (NLRP3) inflam-
masome, an innate immune sensor and multimeric protein complex
that initiates an inflammatory form of cell death and triggers the
release of the proinflammatory cytokines IL‐1β and IL‐18. Contact
allergens such as nickel, trinitro‐chlorobenzene, chromium and latex
as well as the skin irritant sodium dodecyl sulfate (SDS) induce NLRP3
inflammasome‐mediated IL‐1β secretion in keratinocytes and mac-
rophages.8‐11 Furthermore, inflammasome‐deficient mice display
impaired early phase reactions during contact allergen challenge.8
Inflammasome‐mediated cytokines induce the activation of dendritic
and Langerhans cells, endothelial cells and in case of allergic contact
dermatitis the recruitment of antigen‐specific T‐cells. Thus, inflam-
masome pathway inhibition may be an effective strategy for the
treatment of allergic and irritant contact dermatitis.
The development of novel therapies is amajor unmetmedical need
in contact dermatitis and inhibition of the NLRP3‐inflammasome
pathway is a promising approach. In search for inhibitors of the
NLRP3 inflammasome, we performed a high content screen with
41,184 small molecules by using a recently established reporter
cell line expressing a fluorescently tagged apoptosis associated speck‐
like protein containing a CARD (ASC).12 Here, we report the identifi-
cation of disulfiram, a known carbamate derivative, to be a dose‐
dependent inhibitor of inflammasome activation in vitro and inhibitor
of eczema in a patch test model of irritant contact dermatitis in vivo.
2 | METHODS
2.1 | High content screen and selectivity screens for
inflammasome inhibitors in murine cells
High content screening was performed with 41,184 small molecules
including drugs from Selleck, World Drug Index (WDI) derived mol-
ecules,13 the Library of pharmacologically active compounds (LOPAC,
Sigma Aldrich) and non‐commercial compounds from academia. For
the high content screen we used an immortalized murine macrophage
reporter cell line expressing a fluorescently tagged ASC (ASC‐
mCerulean) that we recently established.12 At inactive state, the
inflammasome adapter molecule ASC is expressed as a soluble
cytoplasmatic protein. Upon inflammasome stimulation by activators
such as adenosine triphosphate (ATP) or nigericin, ASC assembles
into a detectable cytosolic multi‐protein complex named ASC
“speck”. The ASC speck formation represents an indicator of
inflammasome activation as it correlates with the subsequent
cleavage of caspase‐1 and IL‐1β production. All compounds including
the previously reported inflammasome inhibitor MCC95014 as posi-
tive control and vehicle (DMSO) as negative control, were screened
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for activity at 10 μM concentration for inhibition of ATP‐induced
ASC speck formation in the ASC‐mCerulean reporter cell line using
a fully automated microscope (ArrayScan, Cellomics Inc.). For details
on the high‐throughput screening procedure and data analysis, please
refer to Supporting Information S1.39 In short, active candidates from
primary screening were confirmed in a second, independent round of
screening, in which also the selectivity for different types of inflam-
masome activation was investigated: either using ATP (original
screening condition), ATP plus lipopolysaccharides (LPS), or nigericin
for inflammasome activation. Furthermore, the effect on IL‐1β pro-
duction was assessed using an ELISA assay. Compounds with signif-
icant inhibition in all conditions were selected for determination of
the half maximal inhibitory concentration (IC50) and viability testing
at concentrations ranging from 20 μM down to 0.02 μM in the mu-
rine reporter cell line (for LPS and ATP‐induced inflammasome
activation, measurement in triplicates). The substances were finally
selected as hit candidates on the basis of their IC50 dose response
profile, chemical structure and potential for chemical optimization
and cell count stability (Supporting Information S1).
2.2 | IC50 determination in human THP1 reporter
cells and cytokine responses in human peripheral
blood monocytes
IC50 values of hit compounds were also assessed for the human sys-
tem using THP1 ASC‐GFP reporter monocytes (Invivogen®) analog to
the murine reporter cell screening and IC50 delineation process
(Supporting Information S1). Additionally, inhibition of IL‐1β and IL‐18
secretion from human peripheral blood monocytes was evaluated. To
obtain the monocytes, peripheral blood mononuclear cells from hu-
man venous blood were harvested using density gradient centrifuga-
tion and seeded into adhesion cell culture plates containing RPMI
1640 (Biochrom) with 10% FBS, 1% penicillin/streptomycin and
50 mg/ml Normocin® (Invivogen). After 2 h of incubation (37°C, 5%
CO2), the medium containing non‐adherent cells was removed and
discarded. The remaining adherent cells (primary monocytes) were
carefully washedwithmedium and used for further experiments. After
overnight priming with LPS, cells were stimulated with hit compounds
for 1 h, followed by inflammasome activation with ATP. IL‐1β in su-
pernatant was measured by ELISA. IL‐18 secretion by human mono-
cytes was measured using a bead‐based multiplex cytokine assay (for
details, please refer to the Supporting Information S2).
2.3 | In vivo studies in healthy volunteers and study
design
For inclusion, the participants had to be ≥ 18 years and had to be able
to read, understand and to be willing to sign the informed consent
form and abide with study procedures. Exclusion criteria included
skin diseases such as psoriasis or infectious skin diseases (viral, bac-
terial, fungal infections), ongoing treatment with immunosuppressive
drugs or phototherapy, an immunosuppressive condition, pregnancy,
breast feeding and a known intolerance to mometasone furoate,
disulfiram or base cream. The study was approved by the local ethics
committee (EA1/160/17), and healthy subjects provided written and
oral informed consent before any study‐related procedures (for de-
tails, please refer to the Supporting Information S3).
In the first part of the study as proof of concept, three different
concentrations of disulfiram and vehicle were applied on the skin of
the inner forearm of 16 healthy volunteers using the Curatest®
patches (Rengsdorf). After 24 h, patches were removed, and each
treated area was incubated with SDS 5% (2 drops) and the test patch
was applied for additional 24 h. After further 48 h, the clinical
response was assessed (Figure S1A).
The second, double‐blind and placebo‐controlled part of the
study was conducted in 25 healthy subjects and consisted of four
visits on four consecutive days. On day 1, (i) 5% disulfiram in base
cream, (ii) mometasone furoate 0.1% in base cream and (iii) base
cream (vehicle) were applied on non‐irritated intact skin of the inner
forearm using the patches as before. After 24 h of incubation, the
patch tests were removed and SDS 5% (2 drops) was applied on all
three treated skin areas covered by patches for 24 h. On day 3, the
patches were removed and on day 4 the clinical responses were
assessed (Supporting Information S1 and Figure S1B).
2.4 | Assessment of erythema and skin blood flow
Erythema levels were assessed by reflectance spectrophotometry
(Mexameter; Courage – Khazaha) and expressed as arbitrary units
(AU, range: ‐ 999). For measurement of mean flux of lesional cuta-
neous blood circulation laser‐speckle imaging by Moor FLPI blood
flow imager (Moor Instruments Ltd.) was applied. This technique is
based on laser Doppler imaging and skin blood flow levels are
expressed in perfusion units (PU).
2.5 | Assessment of skin cytokine concentrations
The D‐Squame® technique was used for sampling of lesional cor-
neocytes followed by quantification of inflammasome‐mediated
cytokine concentrations. From each skin lesion, 30 consecutive tape
strips (D104 ‐ D‐Squame® Standard Sampling Discs, Clinical and
Derm) were sampled. Only the last three tape strips, representing the
upper epidermal layers were sampled in tubes (2 ml Eppendorf tubes)
containing 100 μl of a solution with RIPA buffer (10%, Ref 06/2011
#9806S, Cell signaling technology), protease inhibitor cocktail (10%,
#11697498001, Roche Diagnostics GmbH) and distilled water 80%.
After 1 h of room temperature incubation with gentle agitation, the
samples were stored at −20°C until further use. Before measurement,
samples were briefly centrifuged and the three supernatants per
subject and treatment were pooled. Levels of cytokines IL‐1β and IL‐
18weremeasured in duplicate by ELISA (human IL‐1βDuoSet DY201,
human IL‐18 DuoSet DY318‐05, R&D Systems) and assessed in pg/ml.
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F I GUR E 1 Disulfiram induced a dose‐dependent inhibition of ASC speck formation and cytokine release in cellular assays in vitro.
Fluorescence images showing (A) single nuclei of the murine macrophage reporter cell line without activation vs. (B) activated murine
macrophage reporter cells upon Adenosine triphosphate (ATP) stimulation with subsequent Apoptosis associated speck‐like protein
containing a CARD (ASC) speck formation (green ASC‐mCerulean) as an indicator of inflammasome activity. Inhibition of ATP‐induced ASC
speck formation by (C) Disulfiram 5 μM and (D) 10 μM. Nuclei are counterstained with DRAQ5 (red) (Original magnification x20) (E) Dose‐
dependent inhibition of ATP‐induced ASC‐speck formation (relative activity in % in relation to maximal ASC‐formation achieved by ATP‐
stimulation of controls) by disulfiram (red curve) in the murine macrophage reporter cell line. MCC950 served as reference substance (blue
curve). The results show the data of three replicates. Mean and standard deviation (SD) are shown for each value. (F) Disulfiram inhibits ATP‐
induced ASC speck formation in human THP1 ASC‐GFP reporter monocytes dose‐dependently (red curve). MCC950 served as reference
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2.6 | Data and statistical analyses
Statistical analysis was performed for non‐parametric data by using
the Friedman‐Test. The IC50 of primary hits was determined by
fitting the data to a four parameter logistic equation (Nonlinear
Regression, Sigmoidal, 4PL) in GraphPad Prism as described previ-
ously.15 For all analyses, SPSS version 22.0 and Graph Pad Prism
version 6.0 were used. A p‐value of ≤0.05 was considered to indicate
statistical significance.
3 | RESULTS
3.1 | High content screen identifies Disulfiram as a
potent NLRP3 inflammasome pathway inhibitor in
murine macrophages
In the primary high content screen of 41,184 small molecules, we
selected a total of 352 inhibitory compounds via their capacity to
inhibit inflammasome activation by assessment ATP‐induced ASC‐
speck formation in the murine macrophage reporter cell line and
exclusion of cytotoxic and auto‐fluorescent compounds.
In the following selectivity screen, we observed a significant in-
hibition of ASC speck formation for 56 molecules in the three condi-
tions ATP‐ and nigericin‐induced inflammasome activation as well as
inhibition of IL‐ 1β production of ATP and LPS‐treated murine mac-
rophages. Subsequent dose/response assays with 11 different con-
centrations (20–0.02 μM) for all three conditions narrowed the list
down to 48 compounds. Based on the chemical structure, potential for
chemical optimization and cell count stability, we selected 10 com-
pounds as candidates of interest. Among those eligible compoundswas
the thiuramdisulfide‐derived drug disulfiram. Disulfiram (C10H20N2S4)
is licensed for chronic alcoholism (Antabuse®) as an oral drug.
Disulfiram inhibited the ATP‐induced ASC speck formation in the
murine macrophage reporter cell line dose‐dependently with an IC50
of 4.39 μM. In comparison, the IC50 of the other nine candidates of
interest ranged between 0.5 and 7.5 μM (for further information,
please refer to Supporting Information S1) while the reference sub-
stance MCC950 had an IC50 of 0.47 μM (Figure 1A–E). Disulfiram
was selected from the 10 hit compounds due to its approval for
human use and its previous application in nickel‐induced allergic
contact dermatitis.
3.2 | Disulfiram dose‐dependently inhibits ASC
speck formation and cytokine secretion from human
monocytes
Analogously to the murine reporter cell screening and IC50 delin-
eation process, IC50 values of hit compounds were also assessed in
human cells using THP1 ASC‐GFP reporter monocytes for the
assessment of ASC speck formation and human primary monocytes
for inhibition of IL‐1β and IL‐18 secretion.
In line with the murine data, we could observe a dose‐dependent
inhibition of ATP‐induced ASC speck formation by disulfiram in the
human THP1 ASC‐GFP reporter monocytes (Figure 1F). Here, the
IC50 of disulfiram was 3.19 μM, whereas the IC50 of MCC950
averaged 1.97 μM. Likewise but less strongly, disulfiram dose‐
dependently inhibited the ATP‐ and LPS‐induced IL‐1β production
in human monocytes with an IC50 of 7.38 μM compared to 0.06 μM
for MCC950 (Figure 1G). Besides IL‐1β, disulfiram at 10 μM con-
centration also markedly reduced the secretion of IL‐18 by 56.6%
(SD = 11.0) in human monocytes (Figure 1H).
3.3 | Topical disulfiram dose‐dependently inhibits
SDS‐induced irritant contact dermatitis
As an in vivo first proof of concept, we next studied disulfiram for its
potential to inhibit irritant contact dermatitis (induced by SDS) in a
human patch test model. Therefore, topical disulfiram in different
concentrations (0.5%, 2% and 5% in base cream) and vehicle (base
cream) were applied on the volar forearm skin of 16 healthy volun-
teers for 24 h. Afterward, treated skin areas were incubated with
SDS 5% for additional 24 h and clinical responses were assessed after
further 48 h (Figure S1A).
Here, disulfiram treatment inhibited SDS‐induced inflammation
by dose‐dependently reducing erythema levels of skin lesions as
compared to vehicle (base cream) (Figure 2). As assessed by reflec-
tance spectrophotometry, erythema levels (mean ± SD) were 28%
lower after treatment with 5% disulfiram than with vehicle with
significant difference (212.3 ± 52.1 vs. 293.2 ± 66.6 AU). Erythema
levels after treatment with 2% and 0.5% disulfiram, respectively,
were 239.9 ± 61.5 and 245.0 ± 59.4 AU. The treatment effect ach-
ieved with 0.5% disulfiram was significantly less effective as
compared to 5% disulfiram but not vehicle (Figure 2B).
substance (blue curve). The results show the data of three replicates. Mean and SD are shown for each value. (G) Dose‐dependent inhibition of
Interleukin (IL)‐1β release by disulfiram in human monocytes which were stimulated with ATP and Lipopolysaccharides (LPS) (red curve)
compared to reference substance MCC950 (blue curve). IL‐1β release shown as the proportion of the LPS‐ and ATP‐induced release of
monocytes in absence of Disulfiram. Mean and standard error of the mean are shown for each value. The graphic shows the results of seven
independent experiments. (H) Inhibition of IL‐18 release by disulfiram. Culture supernatants of human monocytes stimulated with LPS + ATP in
the presence or absence of disulfiram or MCC950 from three different donors were analyzed by cytokine bead arrays. Relative IL‐18 release (%)
in presence of compound as compared to positive control (LPS + ATP) is shown. Bars indicate mean values. The concentrations of disulfiram
(10 μM) and MCC950 (0.04 μM) for this assay were selected according to the molar range of their respective IC‐50 derived from the IL‐1β assay
on monocytes
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3.4 | Disulfiram is more effective than placebo and
at least as effective as mometasone in the treatment
of SDS‐induced irritant contact dermatitis
In the second double‐blind randomized controlled part of the study
with 25 subjects, topical application of disulfiram 5%, mometasone
0.1% or vehicle (base cream) for 24 h on the volar forearm was fol-
lowed by application of sodiumdodecylsulfate 5% (SDS) on treated
skin areas for 24 h each and clinical responses were assessed after
further 48 h.
Topical treatment with disulfiram 5% significantly reduced SDS‐
induced irritant contact dermatitis as compared to placebo (Figure 3).
Erythema levels of skin lesions (mean ± SD), assessed by reflectance
spectrophotometry, were 18% lower after treatment with disulfiram
than with placebo with significant difference (272.5 ± 60.0 vs.
333.3 ± 60.4 AU). Also, blood flow in SDS‐induced skin lesions was
significantly reduced by 47% as measured by laser speckle imaging
(disulfiram: 195.8 ± 150.2 PU; placebo: 369.8 ± 188.2 PU).
Treatmentwith the class III glucocorticosteroidmometasone 0.1%
significantly reduced blood flow compared to placebo
(233.1±150.1PU;−37%), but not erythema levels in SDS‐induced skin
lesions (329.6 ± 69.9; −1%). Disulfiram was as effective as mometa-
sone in reducing bloodflowand significantlymore effective in reducing
erythema levels in SDS‐induced skin inflammation (Figure 3A–D).
The topical application of all compounds was well tolerated by
the participants. During the study, neither side effects nor allergic
skin reactions were reported. The subsequent resolution of eczem-
atous skin lesions was unremarkable in all participants.
3.5 | Treatment with disulfiram reduces corneocyte
cytokine levels in SDS‐induced irritant contact
dermatitis.
Corneocyte concentrations of the inflammasome‐mediated cytokines
IL‐1β and IL‐18 in treated skin lesions (disulfiram 5%, mometasone
0.1% or vehicle) of SDS‐induced irritant contact dermatitis were
assessed by tape stripping and ELISA 48 h after application of SDS.
Treatment with disulfiram 5% resulted in significantly lower IL‐18
levels (1.6 ± 1.1 pg/ml) as compared to placebo (3.5 ± 2.9 pg/ml;
−54%) but not as compared to mometasone (4.9 ± 13.2 pg/ml)
(Figure 3E).
Cutaneous IL‐1β concentrations were very low and not detect-
able in most samples. Therefore, no significant effects were observed
between the three different treatments (data not shown).
F I GUR E 2 Topical disulfiram dose‐dependently inhibits SDS‐
induced irritant contact dermatitis. Patch test model. Healthy
volunteers were pre‐treated with disulfiram in different
concentrations (0.5%, 2% and 5%) or vehicle for 24 h, followed by
application of Sodiumdodecylsulfate (SDS) for 24 h. (A) Dose‐
dependent inhibition of erythema by pretreatment with disulfiram
in base cream. Strong erythema reaction after pretreatment with
vehicle, moderated erythema after pretreatment with 0.5% disul-
firam, minimal erythema after 2% disulfiram and nearly absence of
erythema by pretreatment with 5% disulfiram. Representative
example of erythema reaction in one healthy volunteer. (B) Assess-
ment of erythema levels by mexameter in n = 16 healthy volunteers
of the disulfiram 0.5%, 2% and 5% and vehicle pre‐treated skin. Bars
indicate mean values
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F I GUR E 3 Disulfiram is more effective than placebo and at least as effective as mometasone in the treatment of SDS‐induced irritant
contact dermatitis. Double‐blind, placebo‐controlled pathophysiology study in n = 25 healthy volunteers: Disulfiram inhibits SDS‐induced
irritant contact dermatitis. (A) Assessment of erythema by mexameter in n = 25 healthy volunteers of the disulfiram 5%, vehicle and
momentasone furoate 0.1% pre‐treated skin. Significant reduction of erythema in disulfiram 5% pretreated healthy volunteers compared to
mometasone furoate 0.1% treatment and vehicle. Bars indicate mean values. (B) Exemplified clinical picture of erythema reaction in one healthy
volunteer. (C) Assessment of perfusion by Laser Speckle Imaging in n = 25 healthy volunteers of the disulfiram 5%, vehicle and mometasone
furoate 0.1% pre‐treated skin. Significant reduction of blood flow in disulfiram 5% pretreated healthy volunteers compared to vehicle treated
group. Bars indicate mean values. (D) Representative example of blood flow assessment by Laser Speckle Imaging in one healthy volunteer.
(E) Interleukin (IL)‐18 levels in disulfiram, mometasone furoate 0.1% and vehicle pretreated groups measured in pg/ml by ELISA. Significant
reduction of corneocyte IL‐18 levels in disulfiram 5% pretreated healthy controls compared to vehicle. Bars indicate mean values
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4 | DISCUSSION
Our study shows that disulfiram is a potent and dose‐dependent
inhibitor of the NLRP3 inflammasome pathway and that
topical treatment with disulfiram is effective in inhibiting irritant
contact dermatitis. These findings support the development of
inflammasome‐targeted therapies for patients with contact derma-
titis such as chronic hand eczema and should prompt further trials to
explore the therapeutic potential of topical disulfiram in this disease.
Since the introduction of large‐scale screening technologies in
drug discovery, a number of novel drug candidates but also approved
drugs with high potential for repurposing were identified. These
included compounds for genetic, neoplastic or infective diseases.16‐18
The use of an inflammasome reporter cell line for high content
screen is an established method and ATP‐induced ASC speck for-
mation was formerly shown by us to correlate well with caspase‐1
cleavage and IL‐1β production.12 Compared to the reference sub-
stance MCC950, disulfiram revealed a dose‐dependent, although less
potent, inhibition of NLRP3 inflammasome activation in murine and
human cellular assays. The superiority of MCC950 compared to
disulfiram was highest in the suppression of IL‐1β production in hu-
man monocytes. One explanation for these differences could be
different modes of action of MCC950 and disulfiram. While MCC950
was shown to directly block canonical and non‐canonical NLRP3
inflammasome activation, disulfiram’s mode of action is less defined
and rather considered to be an indirect effect.19 For MCC950, as in
our study, differences in IC50 levels between ASC speck formation
and IL‐1ß release were previously reported. This was explained by
the nature of the ASC reporter cell line, which does not require LPS
priming owing to its constantly high NLRP3 expression.14 Although
MCC950 demonstrated to be effective in different inflammatory
disorders, it was not further developed due to hepatotoxicity in pa-
tients with rheumatoid arthritis during phase II clinical trials.20
In allergic or irritant contact dermatitis, NLRP3 inflammasome
activation is induced by allergens and irritants respectively, and this
results in cutaneous secretion of pro‐inflammatory cytokines IL‐1β
and IL‐18.8‐11 To assess the potential of disulfiram to inhibit
inflammasome pathway activation in vivo, we established a patch test
model of irritant contact dermatitis. The different disulfiram con-
centrations (0.5%, 2% and 5%) were in part derived from an approved
antiscabiotic agent (Tenutex®, disulfiram 2%) and anti‐glaucoma eye
drops (disulfiram 0.5%).21,22 SDS, also known as sodium lauryl sulfate
(SLS), is a surfactant molecule that results in lipid extraction and
swelling of the exposed skin.23 Recently, SDS was shown to induce
NLRP3 inflammasome activation in keratinocytes and macrophages.8
SDS is an obligatory irritant to the skin and is routinely used in 0.25%
concentration to assess skin irritability in patients undergoing patch
testing.24 In addition, SDS in concentrations up to 10% is applied as a
chemical irritant in percutaneous absorption and irritant contact
dermatitis models in human skin in vivo.23
SDS‐induced eczema models were formerly used to assess the
anti‐inflammatory potential of several topically applied herbal sub-
stances.25‐28 Protective effects of Isatis tinctoria L, marigold,
rosemary and Poria cocos were observed when applied in parallel
with SDS during the eczema induction phase.25‐27 Comparison to
standard glucocorticosteroid treatment was done in one study only
without any superiority of the herbal compounds.26 Our data are
partially consistent with earlier findings showing reduced inflamma-
tory responses in SDS‐induced eczema pre‐treated with topical
glucocorticosteroids.29
In agreement with the anti‐inflammatory effects of topical
disulfiram in our study, systemic treatment with disulfiram previously
showed to be effective in patients with active, nickel‐induced allergic
contact dermatitis. Altogether three studies with oral disulfiram (two
placebo‐controlled trials and one open‐label trial) were performed.
Disulfiram doses ranged from 125 to 250 mg/d and treatment
duration varied between 4 and 8 weeks. Outcomes showed higher
complete responder rates for disulfiram in both placebo‐controlled
trials (45% vs. 15% and 91% vs. 10%) and significant clinical
improvement in the majority of patients in the open‐label study.30‐32
Notably, hepatotoxicity was observed in single patients treated with
disulfiram for hand eczema.30,31 In line with this, disulfiram‐induced
liver toxicity is the most common side effect in patients with alco-
holism, for which disulfiram was originally approved based on its
inhibitory effect on the acetaldehyde dehydrogenase. Due to further
side effects such as neuropathy and possible embryotoxicity, sys-
temic disulfiram treatment is less frequently used nowadays.
In our patch test model, disulfiram was in part superior in pre-
venting inflammation as compared to mometasone. In contrast to
glucocorticosteroids, no broad immunosuppressive effects, skin at-
rophy or telangiectasia are known from disulfiram usage.33
Its topical use as prescription free medication for whole body use
in any age is licensed in Sweden andwell tolerated.21 Besides the use of
emollients and avoidance of allergens/irritants, eczema‐preventive
treatments are not available. In particular, patients with occupational
irritant contact dermatitis could benefit from a protective effect by
pro‐active application of disulfiram, thus positively affecting the pa-
tients’ working ability and quality of life. Although the topical appli-
cationof disulfiramwaswell tolerated, its repetitive usemaybear a risk
of sensitization. In construction workers with suspected occupational
disease and sensitization to rubber components, disulfiram was a
common allergen.34 Also, a study on patients with suspected allergic
contact dermatitis (n = 2260) demonstrated a disulfiram sensitization
in 4.8% of the cases.35 Therefore, the use and dosage of topical disul-
firam on inflamed skin need to be assessed over long‐term use.
The mode of action by which disulfiram exerts its anti‐
inflammatory effects is not completely understood. When disul-
firam was earlier used in nickel‐induced allergic contact dermatitis, it
was assumed to act via nickel chelation.31 Recent insight showing
inflammasome activation to be a relevant pathomechanism in allergic
and irritant contact dermatitis8‐11 and the in vitro (IL‐1β and IL‐18)
and in vivo (IL‐18) decrease of cytokine levels in our study suggest
that disulfiram acts via inhibition of inflammasome pathway activa-
tion. Recent data support the use of disulfiram in other auto-
inflammatory conditions such as gout and peritoneal inflammation.19
Disulfiram was shown to inhibit the cytoplasmic release of lysosomal
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cathepsin B resulting in inactivation of the NLRP3 inflammasome.
Furthermore, it reduced NADPH oxidase‐derived ROS production.19
Of further interest, disulfiram was found to inhibit gasdermin D pore
formation.36 Whether or not gasdermin D participates in pro‐
inflammatory cell death by pyroptosis in the context of allergic
and/or irritant contact dermatitis remains open.
Limitations of our study comprise the considerable variability of
the assessed clinical parameters, as well as the lack of data on long‐
term and therapeutic use of topical disulfiram on inflamed skin, which
would require a phase II clinical trial. Based on the favorable effects
of systemic disulfiram treatment in patients with nickel‐induced
allergic contact dermatitis, its topical use in active disease repre-
sents a promising approach.
In contrast to IL‐18, we could not detect cutaneous IL‐1β levels in
healthy volunteers. This may be explained by the rapid local degrada-
tion of IL‐1β in the tissue as described in other IL‐1‐mediated disor-
ders.37 Accordingly, only few IL‐1β‐expressing cells were previously
detected in lesional skin of allergic and irritant contact dermatitis, and
these did not change over time (6 to 72 h).38 However, it should be
noted that only upper epidermal layerswere examined in our study and
dermal cytokine concentrations were not assessed.
In conclusion, we demonstrate a dose‐dependent anti‐
inflammatory effect of disulfiram in an experimental study of irri-
tant contact dermatitis. Our results further encourage to investigate
the efficacy and safety of topical disulfiram over long term use in
inflammasome‐mediated skin diseases. For this, chronic hand eczema
due to allergic and/or irritant contact dermatitis would be an excel-
lent condition to study.
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